Twist Bioscience, a synthetic biology company, laid off approximately 270 employees, representing about 25% of its workforce, in a restructuring effort announced in early 2024. The move aims to reduce costs and extend the company's financial runway, focusing resources on core DNA synthesis and data storage businesses. This significant reduction reflects broader challenges and consolidation within the biotechnology and life sciences tools industry.
